XBiotech Reports Positive Phase II Efficacy for XB2001 in Metastatic Colorectal Cancer

AI-generated NewsSnap summary based on source reporting.
Published: 2026-10-19
Category: health
Source: BioSpace
Original source

XBiotech Inc. announced positive final efficacy results from the Phase II TASKIN clinical trial for its anti-IL-1α monoclonal antibody, XB2001 (Natrunix™), in refractory metastatic colorectal cancer. The study met its primary endpoint, showing 61.3% 12-month overall survival in the experimental arm, surpassing the pre-specified threshold and suggesting a potential new treatment option.

Want more?

Open NewsSnap.ai for the full app experience, including audio, personalization, and more news tools.

Open NewsSnap.ai